







Lab No. : DUR/23-03-2024/SR8904529

: F

Patient Name : BANI GANGULY Age :40 Y 8 M 0 D

Lab Add. : Newtown, Kolkata-700156 Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 23/Mar/2024 10:11AM

: 23/Mar/2024 05:21PM Report Date



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
-----------	--------	-------------------	------	--

PHOSPHORUS-INORGANIC,BLOOD, GEL 2.4-5.1 mg/dL mg/dL

Gender

SERUM (Method:Phosphomolybdate/UV)

*** End Of Report ***

MBBS MD (Biochemistry) Consultant Biochemist Reg No. WBMC 62456



Lab No. : DUR/23-03-2024/SR8904529

: F

Patient Name : BANI GANGULY

Age : 40 Y 8 M 0 D

Gender

Lab Add. : CITY CENTER, DURGAPUR PIN-713

: 23/Mar/2024 10:11AM

Ref Dr. : Dr.MEDICAL OFFICER

Report Date : 23/Mar/2024 02:31PM

Collection Date



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit	
SGOT/AST (Method:IFCC Kinetic Method)	12	< 40	U/L	
SGPT/ALT (Method:IFCC Kinetic Method)	9	< 41	U/L	
POTASSIUM,BLOOD (Method:ISE DIRECT)	5.00	3.1-5.5 mEq/L	mEq/L	
UREA,BLOOD (Method:UREASE-GLDH)	22.3	12.8-42.8	mg/dl	
CALCIUM,BLOOD (Method:ARSENAZO III)	8.90	8.6 - 10.2 mg/dl	mg/dL	
URIC ACID,BLOOD (Method:URICASE)	4.40	2.6 - 6.0	mg/dl	
*TOTAL PROTEIN [BLOOD] ALB:0	GLO RATIO , .			
TOTAL PROTEIN (Method:BIURET METHOD)	<u>6.30</u>	6.6 - 8.7	g/dL	
ALBUMIN (Method:BCG)	3.9	3.5-5.2 g/dl	g/dl	
GLOBULIN (Method:Calculated)	2.40	1.8-3.2	g/dl	
AG Ratio (Method:Calculated)	1.63	1.0 - 2.5		
GLUCOSE,PP (Method:GOD POD)	<u>187</u>	(70 - 140 mg/dl)		

PLEASE CORRELATE CLINICALLY AND WITH DIATERY HISTORY.

*GLYCATED HAEMOGLOBIN (HBA1C) , EDTA WHOLE BLOOD

GLYCATED HEMOGLOBIN (HBA1C) 5.5 ****FOR BIOLOGICAL REFERENCE % INTERVAL DETAILS , PLEASE REFER TO THE BELOW MENTIONED REMARKS/NOTE WITH ADDITIONAL CLINICAL INFORMATION ***

HbA1c (IFCC) 37.0 mmol/mol (Method: HPLC)

Clinical Information and Laboratory clinical interpretation on Biological Reference Interval:

Analyzer used: BIORAD D-10

Method: HPLC

Recommendations for glycemic targets

- Ø Patients should use self-monitoring of blood glucose (SMBG) and HbA1c levels to assess glycemic control.
- Ø The timing and frequency of SMBG should be tailored based on patients' individual treatment, needs, and goals.
- Ø Patients should undergo HbA1c testing at least twice a year if they are meeting treatment goals and have stable glycemic control.
- Ø If a patient changes treatment plans or does not meet his or her glycemic goals, HbA1c testing should be done quarterly.

Lab No. : DUR/23-03-2024/SR8904529

Page 2 of 10



 Patient Name
 : BANI GANGULY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 40 Y 8 M 0 D
 Collection Date
 : 23/Mar/2024 10:11AM

 Gender
 : F
 Report Date
 : 23/Mar/2024 02:31PM



DEPARTMENT OF BIOCHEMISTRY

Test Name	Result	Bio Ref. Interval	Unit

 \emptyset For most adults who are not pregnant, HbA1c levels should be <7% to help reduce microvascular complications and macrovascular disease . Action suggested >8% as it indicates poor control.

 \varnothing Some patients may benefit from HbA1c goals that are stringent.

Result alterations in the estimation has been established in many circumstances, such as after acute/ chronic blood loss, for example, after surgery, blood transfusions, hemolytic anemia, or high erythrocyte turnover; vitamin B_{12} / folate deficiency, presence of chronic renal or liver disease; after administration of high-dose vitamin E / C; or erythropoietin treatment.

Reference: Glycated hemoglobin monitoring BMJ 2006; 333;586-8

References

- 1. Chamberlain JJ, Rhinehart AS, Shaefer CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. Published online 1 March 2016. doi:10.7326/M15-3016.
- 1 Middl 2016. 001. 10.7326/Middl 1, Hoshino T, Jeppsson JO, John WG, Little RR, Miedema K, Myers GL, Reinauer H, Sacks DB, Weykamp CW. International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division. Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group. Clin Chem Lab Med. 2007;45(8):1077-1080.

PDF Attached

r Dr Attacheu			
*LIPID PROFILE, GEL SERUM			
CHOLESTEROL-TOTAL (Method:CHOD PAP Method)	166	Desirable: < 200 mg/dL Borderline high: 200-239 High: > or =240 mg/dL	mg/dL
TRIGLYCERIDES (Method:GPO-PAP)	248	NORMAL < 150 BORDERLINE HIGH 150-199 HIGH 200-499 VERY HIGH > 500	mg/dL
HDL CHOLESTEROL (Method:DIRECT METHOD)	57	42-88 mg/dl	mg/dL
LDL CHOLESTEROL DIRECT (Method:Direct Method)	90	OPTIMAL: <100 mg/dL, Near optimal/ above optimal: 100-129 mg/dL, Borderline high: 130-159 mg/dL, High: 160-189 mg/dL, Very high: >=190 mg/dL	mg/dL
VLDL (Method:Calculated)	19	< 40 mg/dl	mg/dL
CHOL HDL Ratio (Method:Calculated)	2.9	LOW RISK 3.3-4.4 AVERAGE RISK 4.47-7.1 MODERATE RISK 7.1-11.0 HIGH RISK >11.0	
*BILIRUBIN (TOTAL), GEL SERUM			
BILIRUBIN (TOTAL) (Method:Diazotized DCA Method)	0.40	< 1.2	mg/dL
GLUCOSE,FASTING (Method:GOD POD)	110	(70 - 110 mg/dl)	mg/dL
SODIUM,BLOOD (Method:ISE DIRECT)	<u>134</u>	136 - 145	mEq/L
CREATININE, BLOOD (Method:ENZYMATIC)	0.52	0.60 - 1.1 mg/dl	mg/dL
*THYROID PANEL (T3, T4, TSH), GEL SERUM	1		
T3-TOTAL (TRI IODOTHYRONINE) (Method:CLIA)	1.60	0.9 - 2.2 ng/ml	ng/ml
T4-TOTAL (THYROXINE) (Method:CLIA)	14.8	5.5-16 microgram/dl	5.5-16 microgram/dl
TSH (THYROID STIMULATING HORMONE)	2.2	0.5-4.7	μIU/mL

Lab No.: DUR/23-03-2024/SR8904529 Page 3 of 10



 Lab No.
 : DUR/23-03-2024/SR8904529
 Lab Add.
 : CITY CENTER, DURGAPUR PIN-713.

 Patient Name
 : BANI GANGULY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 40 Y 8 M 0 D
 Collection Date
 : 23/Mar/2024 10:11AM

 Gender
 : F
 Report Date
 : 23/Mar/2024 02:31PM



DEPARTMENT OF BIOCHEMISTRY

Test Name Result Bio Ref. Interval Unit

BIOLOGICAL REFERENCE INTERVAL: [ONLY FOR PREGNANT MOTHERS]

Trimester specific TSH LEVELS during pregnancy:
FIRST TRIMESTER : 0.10 2.50 µ IU/mL
SECOND TRIMESTER : 0.20 3.00 µ IU/mL
THIRD TRIMESTER : 0.30 3.00 µ IU/mL

References:

1.Indian Thyroid Society guidelines for management of thyroid dysfunction during pregnancy. Clinical Practice Guidelines, New Delhi: Elsevier; 2012.

2. Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, et al. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. Thyroid 2011;21:1081-25.

3. Dave A, Maru L, Tripathi M. Importance of Universal screening for thyroid disorders in first trimester of pregnancy. Indian J Endocr Metab [serial online] 2014 [cited 2014 Sep 25]; 18: 735-8. Available from: http://www.ijem.in/text.asp?2014/18/5/735/139221.

BILIRUBIN (DIRECT) (Method:Diazotized DCA Method)	0.20	< 0.3	mg/dL
ALKALINE PHOSPHATASE (Method:AMP)	85	42-98 U/L	U/L
CHLORIDE,BLOOD (Method:ISE DIRECT)	100	98 - 107	mEq/L

*** End Of Report ***

Dr Sayak Biswas MBBS, MD (Pathology) Consultant Pathologist Reg No. WBMC 74506

Lab No. : DUR/23-03-2024/SR8904529 Page 4 of 10







Lab Add.

Ref Dr.



: Newtown, Kolkata-700156

: Dr.MEDICAL OFFICER

: 23/Mar/2024 10:11AM

Lab No. : DUR/23-03-2024/SR8904529

Patient Name : BANI GANGULY

Age : 40 Y 8 M 0 D

40 Y 8 M 0 D Collection Date

Gender : F Report Date : 23/Mar/2024 05:55PM



DEPARTMENT OF HAEMATOLOGY

Test Name Result Bio Ref. Interval Unit

BLOOD GROUP ABO+RH [GEL METHOD] , EDTA WHOLE BLOOD

ABO AB

(Method:Gel Card)

RH POSITIVE

(Method:Gel Card)

TECHNOLOGY USED: GEL METHOD

ADVANTAGES:

- · Gel card allows simultaneous forward and reverse grouping.
- · Card is scanned and record is preserved for future reference.
- · Allows identification of Bombay blood group.
- Daily quality controls are run allowing accurate monitoring.

Historical records check not performed.

*** End Of Report ***

DR. NEHA GUPTA MD, DNB (Pathology) Consultant Pathologist Reg No. WBMC 65104

Lab No. : DUR/23-03-2024/SR8904529



Lab No. : DUR/23-03-2024/SR8904529

 Patient Name
 : BANI GANGULY

 Age
 : 40 Y 8 M 0 D

 Gender
 : F

Lab Add.

: CITY CENTER, DURGAPUR PIN-713

Ref Dr. : Dr.MEDICAL OFFICER

Collection Date : 23/Mar/2024 10:11AM

Report Date : 23/Mar/2024 02:38PM



DEPARTMENT OF HAEMATOLOGY

Test Name	Result	Bio Ref. Interval	Unit

*CBC WITH PLATELET (THROMBOCYTE) COUNT, EDTA WHOLE BLOOD				
HEMOGLOBIN (Method:PHOTOMETRIC)	<u>11.4</u>	12 - 15	g/dL	
WBC (Method:DC detection method)	10.4	4 - 10	*10^3/µL	
RBC (Method:DC detection method)	4.17	3.8 - 4.8	*10^6/µL	
PLATELET (THROMBOCYTE) COUNT (Method:DC detection method/Microscopy) DIFFERENTIAL COUNT	159	150 - 450*10^3	*10^3/µL	
NEUTROPHILS (Method:Flowcytometry/Microscopy)	69	40 - 80 %	%	
LYMPHOCYTES (Method:Flowcytometry/Microscopy)	27	20 - 40 %	%	
MONOCYTES (Method:Flowcytometry/Microscopy)	03	2 - 10 %	%	
EOSINOPHILS (Method:Flowcytometry/Microscopy)	01	1 - 6 %	%	
BASOPHILS (Method:Flowcytometry/Microscopy) CBC SUBGROUP	00	0-0.9%	%	
HEMATOCRIT / PCV (Method:Calculated)	<u>34.7</u>	36 - 46 %	%	
MCV (Method:Calculated)	83.4	83 - 101 fl	fl	
MCH (Method:Calculated)	27.3	27 - 32 pg	pg	
MCHC (Method:Calculated)	32.7	31.5-34.5 gm/dl	gm/dl	
RDW - RED CELL DISTRIBUTION WIDTH (Method:Calculated)	<u>15.0</u>	11.6-14%	%	
PDW-PLATELET DISTRIBUTION WIDTH (Method:Calculated)	33.6	8.3 - 25 fL	fL	
MPV-MEAN PLATELET VOLUME (Method:Calculated)	14.1	7.5 - 11.5 fl		

*** End Of Report ***

Dr Sayak Biswas MBBS, MD (Pathology) Consultant Pathologist Reg No. WBMC 74506

Page 6 of 10

Lab No. : DUR/23-03-2024/SR8904529



Lab No. : DUR/23-03-2024/SR8904529

> : BANI GANGULY Ref Dr. : Dr.MEDICAL OFFICER

Lab Add.

:40 Y 8 M 0 D **Collection Date** Age

:F : 23/Mar/2024 02:59PM Gender Report Date



DEPARTMENT OF X-RAY

DEPARTMENT OF RADIOLOGY X-RAY REPORT OF CHEST (PA)

FINDINGS:

Patient Name

Lung parenchyma shows no focal lesion. No general alteration of radiographic density. Apices are clear. Bronchovascular lung markings are

Both the hila are normal in size, density and position.

Mediastinum is central. Trachea is in midline.

Domes of diaphragm are smoothly outlined. Position is within normal limits.

Lateral costo-phrenic angles are clear.

Cardiac size appears within normal limits.

Bony thorax reveals no definite abnormality.

IMPRESSION:

Normal study.

ADV: Clinical correlation and further relevant investigation.

Kindly note

Please Intimate us for any typing mistakes and send the report for correction within 7 days.

*** End Of Report ***

DR. SUBRATA SANYAL

MBBS (CAL), DMRD (CAL).
CONSULTANT SONOLOGIST AND RADIOLOGIST.



 Patient Name
 : BANI GANGULY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 40 Y 8 M 0 D
 Collection Date
 : 24/Mar/2024 06:44AM

 Gender
 : F
 Report Date
 : 24/Mar/2024 12:31PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

*URINE ROUTINE ALL, ALL, URINE			
PHYSICAL EXAMINATION			
COLOUR	PALE YELLOW		
APPEARANCE	SLIGHTLY HAZY		
CHEMICAL EXAMINATION			
pН	6.0	4.6 - 8.0	
(Method:Dipstick (triple indicator method))	4.00=	4.005 4.000	
SPECIFIC GRAVITY (Method:Dipstick (ion concentration method))	1.025	1.005 - 1.030	
PROTEIN	NOT DETECTED	NOT DETECTED	
(Method:Dipstick (protein error of pH			
indicators)/Manual)	NOT DETECTED	NOT DETECTED	
GLUCOSE (Method:Dipstick(glucose-oxidase-peroxidase	NOT DETECTED	NOT DETECTED	
method)/Manual)			
KETONES (ACETOACETIC ACID,	NOT DETECTED	NOT DETECTED	
ACETONE)			
(Method:Dipstick (Legals test)/Manual)	DDECENT (.)	NOT DETECTED	
BLOOD (Method:Dipstick (pseudoperoxidase reaction))	PRESENT (+)	NOT DETECTED	
BILIRUBIN	NEGATIVE	NEGATIVE	
(Method:Dipstick (azo-diazo reaction)/Manual)			
UROBILINOGEN	NEGATIVE	NEGATIVE	
(Method:Dipstick (diazonium ion reaction)/Manual) NITRITE	NEGATIVE	NEGATIVE	
(Method:Dipstick (Griess test))	NEGATIVE	NEGATIVE	
LEUCOCYTE ESTERASE	NEGATIVE	NEGATIVE	
(Method:Dipstick (ester hydrolysis reaction))			
MICROSCOPIC EXAMINATION			
LEUKOCYTES (PUS CELLS)	1-2	0-5	/hpf
(Method:Microscopy) EPITHELIAL CELLS	1-2	0-5	/hnf
(Method:Microscopy)	1-2	0-5	/hpf
RED BLOOD CELLS	2-3	0-2	/hpf
(Method:Microscopy)			·
CAST	NOT DETECTED	NOT DETECTED	
(Method:Microscopy) CRYSTALS	CALCIUM OXALATE	NOT DETECTED	
(Method:Microscopy)	PRESENT	NOT DETECTED	
BACTERIA	NOT DETECTED	NOT DETECTED	
(Method:Microscopy)			
YEAST	NOT DETECTED	NOT DETECTED	
(Method:Microscopy)			

Note

- 1. All urine samples are checked for adequacy and suitability before examination.
- 2. Analysis by urine analyzer of dipstick is based on reflectance photometry principle. Abnormal results of chemical examinations are confirmed by manual methods.
- 3. The first voided morning clean-catch midstream urine sample is the specimen of choice for chemical and microscopic analysis.
- 4. Negative nitrite test does not exclude urinary tract infections.
- 5. Trace proteinuria can be seen in many physiological conditions like exercise, pregnancy, prolonged recumbency etc.
- 6. False positive results for glucose, protein, nitrite, urobilinogen, bilirubin can occur due to use of certain drugs, therapeutic dyes, ascorbic acid, cleaning agents used in urine collection container.
- 7. Discrepancy between results of leukocyte esterase and blood obtained by chemical methods with corresponding pus cell and red blood cell count by microscopy can occur due to cell lysis.

Lab No. : DUR/23-03-2024/SR8904529 Page 8 of 10



 Patient Name
 : BANI GANGULY
 Ref Dr.
 : Dr.MEDICAL OFFICER

 Age
 : 40 Y 8 M 0 D
 Collection Date
 : 24/Mar/2024 06:44AM

 Gender
 : F
 Report Date
 : 24/Mar/2024 12:31PM



DEPARTMENT OF CLINICAL PATHOLOGY

Test Name Result Bio Ref. Interval Unit

8. Contamination from perineum and vaginal discharge should be avoided during collection, which may falsely elevate epithelial cell count and show presence of bacteria and/or yeast in the urine.

*** End Of Report ***

Dr Sayak Biswas MBBS, MD (Pathology) Consultant Pathologist Reg No. WBMC 74506

Lab No. : DUR/23-03-2024/SR8904529 Page 9 of 10



Lab No. : DUR/23-03-2024/SR8904529

Patient Name

: BANI GANGULY Ref Dr. : Dr.MEDICAL OFFICER

Lab Add.

Age : 40 Y 8 M 0 D Collection Date :

Gender : F Report Date : 23/Mar/2024 03:01PM



DEPARTMENT OF CARDIOLOGY

DEPARTMENT OF CARDIOLOGY REPORT OF E.C.G.

90	Bpm
106	Ms
92	Ms
352	Ms
435	Ms
40	Degree
-9	Degree
15	Degree
:	Normal Sinus rhythm.
	106 92 352 435 40 -9 15

Please correlate clinically

Dr. A Ghosh M.D.DipCard(PGDCC)Apollohospital,chennai CCEBDM.CCMH

Consultant Clinical Cardiologist

Lab No. : DUR/23-03-2024/SR8904529 Page 10 of 10